上海cmc培訓(xùn) post approval changes for finished product

上海cmc培訓(xùn) post approval changes for finished product

ID:40121591

大?。?17.00 KB

頁(yè)數(shù):20頁(yè)

時(shí)間:2019-07-22

上海cmc培訓(xùn) post approval changes for finished product_第1頁(yè)
上海cmc培訓(xùn) post approval changes for finished product_第2頁(yè)
上海cmc培訓(xùn) post approval changes for finished product_第3頁(yè)
上海cmc培訓(xùn) post approval changes for finished product_第4頁(yè)
上海cmc培訓(xùn) post approval changes for finished product_第5頁(yè)
資源描述:

《上海cmc培訓(xùn) post approval changes for finished product》由會(huì)員上傳分享,免費(fèi)在線閱讀,更多相關(guān)內(nèi)容在教育資源-天天文庫(kù)。

1、PostApprovalChangesforFinishedProductLinHong1AAPS/CPAWorkshop,June28-29,2010DisclaimerTheinformationcontainedinthepresentationhasbeencompiledfromvarioussources.Theviewsandopinionsexpressedarethoseoftheindividualpresenterandshouldnotbeattributedtoanyorganiza

2、tionwithwhichthepresenterisemployedoraffiliated.2AAPS/CPAWorkshop,June28-29,2010PostApprovalChangesGuidelineDocumentsUS:SUPAC:IR(1995),MR(1997)SUPAC:IR/MREquipmentGuidance(1999)SUPAC:ExtendedreleaseOralSolidDosageForms,Development,EvaluationandApplicationof

3、In-Vitro/In-VivoCorrelation(1997)ChangestoanApprovedNDAorANDA(2004)3AAPS/CPAWorkshop,June28-29,2010PostApprovalChangesGuidelineDocumentsEU:CommissionRegulation(EC)No726/2004CommissionRegulation(EC)No1234/2008CommissionRegulation(EC)No1084(5)/2003ModifiedRel

4、easeOralandTransdermalDosageForms:SectionsIandIICPMP/QWP/604/96,CPMP/EWP/280/96GuidelineontheInvestigationofBioequivalenceCPMP/EWP/QWP/1401/984AAPS/CPAWorkshop,June28-29,2010UnitedStatesTheguidelinesprovidedetailsofthe…TypeofchangeLevelsofchangeCMCdocumenta

5、tionrequiredtosupportthechange(dissolutionand/orbioequivalencetests,analyticaltesting….)Filingrequirements5AAPS/CPAWorkshop,June28-29,2010UnitedStatesMinorChange(Level1):MinimalpotentialtohaveanadverseeffectAnnualreport(AR)ModerateChange(Level2):Moderatepot

6、entialtohaveanadverseeffectChangesBeingEffected(CBE)ChangesBeingEffected30days(CBE-30)MajorChange(Level3):SubstantialpotentialtohaveanadverseeffectPriorApprovalSupplement(PAS)6AAPS/CPAWorkshop,June28-29,2010UnitedStatesToIndustry:Responsibilitytoclassifycha

7、ngemovedfromFDAtoindustryAllowsmorechangeswithoutpriorFDAapprovalUseofnewtechnologiesManufacturingcostreductionAdequacyofthestudiesmaybequestionedmonthsoryearslaterevenifthechangesarepredictedorapprovedIfthevalidityofAR/CBE/CBE-30changesischallengedthespons

8、ormayberequiredtotracktheaffectedlots/batchesandprovideadditionaldata,quarantineorrecallproductifitisneededGreaterliabilityifthechangeisnotadequatelysupported7AAPS/CPAWorkshop,June28-29,2010EuropeanUni

當(dāng)前文檔最多預(yù)覽五頁(yè),下載文檔查看全文

此文檔下載收益歸作者所有

當(dāng)前文檔最多預(yù)覽五頁(yè),下載文檔查看全文
溫馨提示:
1. 部分包含數(shù)學(xué)公式或PPT動(dòng)畫的文件,查看預(yù)覽時(shí)可能會(huì)顯示錯(cuò)亂或異常,文件下載后無(wú)此問題,請(qǐng)放心下載。
2. 本文檔由用戶上傳,版權(quán)歸屬用戶,天天文庫(kù)負(fù)責(zé)整理代發(fā)布。如果您對(duì)本文檔版權(quán)有爭(zhēng)議請(qǐng)及時(shí)聯(lián)系客服。
3. 下載前請(qǐng)仔細(xì)閱讀文檔內(nèi)容,確認(rèn)文檔內(nèi)容符合您的需求后進(jìn)行下載,若出現(xiàn)內(nèi)容與標(biāo)題不符可向本站投訴處理。
4. 下載文檔時(shí)可能由于網(wǎng)絡(luò)波動(dòng)等原因無(wú)法下載或下載錯(cuò)誤,付費(fèi)完成后未能成功下載的用戶請(qǐng)聯(lián)系客服處理。